A Phase 2 interventional study of Ocrelizumab in Multiple Sclerosis, sponsored by Hoffmann-La Roche. Active, not recruiting at 12 sites in 3 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 24th largest by enrollment, is one of 5 that started in 2020, is the only one in phase 2, reaches primary completion later than 0 of the 13 other live ones, and was the 9th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Hoffmann-La Roche · Sites in Bulgaria, France, Germany and 3 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 5 started in 2020.
This study's enrollment of 23 is below the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 170 across the 27 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
35 studies in Multiple Sclerosis by Hoffmann-La Roche: 6 open now, 17 under way, 7 of them phase 3. Of 14 finished, 7 (50%) have results posted.
Among the 35 studies in Multiple Sclerosis by Hoffmann-La Roche, this one is the 28th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2020, is one of 6 in phase 2, reaches primary completion later than 1 of the 16 other live ones, and was the 14th registered.
Hoffmann-La Roche’s Multiple Sclerosis studies by the year they started, since 2004.
1 of the studies testing ocrelizumab in Multiple Sclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04466150University of California, San FranciscoImpact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing ocrelizumab in Multiple Sclerosis, from their registry updates:
Among Hoffmann-La Roche’s 35 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a body weight from \>/= 25 kg to \< 40 kg (with at least 2 participants with a body weight from \>/= 25 kg to \</= 35 kg) will receive 300 milligram (mg) ocrelizumab
Drug: Ocrelizumab
Participants with a body weight \>/= 40 kg (with at least 2 participants with a body weight \>/= 40 kg but \</= 50 kg) will receive 600 mg ocrelizumab
Drug: Ocrelizumab
Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight from \>/= 25 kg to \< 40 kg may be enrolled and receive another dose level of ocrelizumab
Drug: Ocrelizumab
Based on PK, PD, safety, and tolerability data analyses of Cohorts 1 and 2, additional participants with a body weight \>/= 40 kg may be enrolled and receive another dose level of ocrelizumab
Drug: Ocrelizumab
Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks. Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab
The population PK model was used to simulate concentration-time course and predict individual area under the concentration versus time curve. The data for the PK parameter: area under the concentration versus time curve was collected and analyzed as per body weight range (\<40kg to ≥40 kg).
Time frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab
The population PK model was used to simulate concentration-time course and predict individual Cmax. The data for the PK parameter: Cmax was collected and analyzed as per body weight range (\<40kg to ≥40 kg).
Time frame: Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood
Time frame: At Week 24
Number of Participants With Adverse Events (AEs)
An AE is untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.
Time frame: Up to 12 years
Dose Exploration Period: Level of Circulating T Cells and Natural Killer (NK) Cells
Time frame: At Week 24
OOE Period: Level of Circulating T Cells and NK Cells
Time frame: Up to 12 years
Dose Exploration Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte
Time frame: At Week 24
OOE Period: Level of Circulating Lymphocyte, Neutrophil, Monocyte and Leukocyte
Time frame: Up to 12 years
Developmental Milestones - Growth Velocity: Change in Height
Time frame: Up to 12 years
Developmental Milestones: Bone Age Assessment by Wrist/Hand Radiographs
Time frame: Up to 12 years
Developmental Milestones: Male and Female Puberty Assessed by Tanner Staging
Time frame: Up to 12 years
Developmental Milestones: Age at Menarche, Related With the Female Reproductive Status
Time frame: Up to 12 years
Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI)
The change in the non-MS CNS pathology was assessed using MRI scans.
Time frame: Up to Week 24
OOE Period: Number of Participants With Shift From Baseline in Non-MS CNS Pathology as Measured by Brain MRI
Time frame: Up to 12 years
Dose Exploration Period: Levels of Blood Immunoglobulins
Time frame: At Week 24
OOE Period: Levels of Blood Immunoglobulins
Time frame: Up to 12 years
Dose Exploration Period: Number of Participants With Antibody Titers Against Standard Vaccines
Measurement of antibody titers to common antigens (mumps, rubella, varicella, and Streptococcus pneumoniae \[S. pneumoniae\]) were performed.
Time frame: At Week 24
OOE Period: Number of Participants With Antibody Titers Against Standard Vaccines
Time frame: Up to 12 years
Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab
Time frame: At Week 24
OOE Period: Number of Participants With ADAs to Ocrelizumab
Time frame: Up to 12 years
Participants took part in the study across 12 investigative sites in 3 countries (the United States, Poland, and Italy). This study is still ongoing.
| Milestone | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Started | 6 | 17 |
| Completed | 6 | 17 |
| Not completed | 0 | 0 |
| Milestone | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Started | 6 | 17 |
| Completed | 0 | 0 |
| Not completed | 6 | 17 |
| Withdrew: Ongoing in study | 5 | 17 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The population PK model was used to simulate concentration-time course and predict individual area under the concentration versus time curve. The data for the PK parameter: area under the concentration versus time curve was collected and analyzed as per body weight range (\<40kg to ≥40 kg).
| microgram/milliters*day (µg/mL*day) | Body Weight < 40 kg | Body Weight ≥ 40 kg |
|---|---|---|
| Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab | 2187 (1565 to 3090) | 3197 (1781 to 4339) |
The population PK model was used to simulate concentration-time course and predict individual Cmax. The data for the PK parameter: Cmax was collected and analyzed as per body weight range (\<40kg to ≥40 kg).
| microgram/milliters (µg/mL) | Body Weight < 40 kg | Body Weight ≥ 40 kg |
|---|---|---|
| Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab | 106 (81 to 142) | 158 (113 to 209) |
| cells/µL | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood | 91.00 (24.0 to 404.0) | 9.00 (1.0 to 151.0) |
An AE is untoward medical occurrence in participant administered a pharmaceutical product \& regardless of causal relationship with this treatment. An AE can therefore be any unfavorable \& unintended sign (including an abnormal laboratory finding), symptom/disease temporally associated with use of investigational product, whether or not considered related to investigational product.
Results for this outcome have not been posted.
| cells/microliter (µL) | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| CD3+ Total T cell | 1637.67 ± 578.50 | 1506.0 ± 468.68 |
| CD4+ Helper T cell | 1044.0 ± 329.0 | 889.18 ± 252.58 |
| CD8+ Cytotoxic T cell | 441.83 ± 180.32 | 532.65 ± 218.52 |
| NK cells | 266.5 ± 182.97 | 237.76 ± 118.63 |
Results for this outcome have not been posted.
| 10^9 cells/L | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Lymphocyte | 1.792 ± 0.660 | 1.668 ± 0.507 |
| Neutrophil | 2.60 ± 0.567 | 2.857 ± 0.762 |
| Monocyte | 0.328 ± 0.151 | 0.343 ± 0.114 |
| Leukocyte | 4.87 ± 1.35 | 5.05 ± 1.06 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
The change in the non-MS CNS pathology was assessed using MRI scans.
| Participants | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Dose Exploration Period: Number of Participants With Shift From Baseline in Non-MS Central Nervous System (CNS) Pathology as Measured by Brain Magnetic Resonance Imaging (MRI) | 0 | 0 |
Results for this outcome have not been posted.
| gram/liter (g/L) | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Total Immunoglobulin | 11.23 ± 1.40 | 11.86 ± 2.92 |
| Immunoglobulin A | 1.27 ± 0.48 | 1.52 ± 0.61 |
| Immunoglobulin G | 9.25 ± 1.20 | 9.73 ± 2.51 |
| Immunoglobulin M | 0.72 ± 0.26 | 0.61 ± 0.31 |
Results for this outcome have not been posted.
Measurement of antibody titers to common antigens (mumps, rubella, varicella, and Streptococcus pneumoniae \[S. pneumoniae\]) were performed.
| Participants | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Mumps | 0 | 0 |
| Pneumococcal Capsular Polysaccharides | 6 | 17 |
| Rubella | 0 | 0 |
| Varicella-Zoster Virus | 0 | 0 |
Results for this outcome have not been posted.
| Participants | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Dose Exploration Period: Number of Participants With Anti-Drug Antibodies (ADAs) to Ocrelizumab | 0 | 0 |
Results for this outcome have not been posted.
Collected over Up to 3.7 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab 300 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Ocrelizumab 600 mg | 0/17 (0%) | 4/17 (23.5%) | 17/17 (100%) |
| Event | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| AppendicitisInfections and infestations | 1/6 | 0/17 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/17 |
| Peripheral swellingGeneral disorders | 0/6 | 1/17 |
| Abscess limbInfections and infestations | 0/6 | 1/17 |
| Candida infectionInfections and infestations | 0/6 | 1/17 |
| Gonococcal infectionInfections and infestations | 0/6 | 1/17 |
| PneumoniaInfections and infestations | 0/6 | 1/17 |
| Alanine aminotransferase increasedInvestigations | 0/6 | 1/17 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 1/17 |
| DehydrationMetabolism and nutrition disorders | 0/6 | 1/17 |
| Event | Ocrelizumab 300 mg | Ocrelizumab 600 mg |
|---|---|---|
| Infusion related reactionInjury, poisoning and procedural complications | 3/6 | 14/17 |
| COVID-19Infections and infestations | 3/6 | 11/17 |
| HeadacheNervous system disorders | 2/6 | 8/17 |
| NasopharyngitisInfections and infestations | 0/6 | 7/17 |
| PyrexiaGeneral disorders | 2/6 | 6/17 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 6/17 |
| Abdominal painGastrointestinal disorders | 2/6 | 2/17 |
| NauseaGastrointestinal disorders | 2/6 | 1/17 |
| FatigueGeneral disorders | 2/6 | 3/17 |
| Disturbance in attentionNervous system disorders | 2/6 | 1/17 |
Safety evaluable population included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Ocrelizumab 300 mg | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Mean | 11.2 ± 0.8 | 15.3 ± 1.8 | 14.2 ± 2.4 |
| Sex: Female, Male(Participants) | Ocrelizumab 300 mg | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Female | 5 | 10 | 15 |
| Male | 1 | 7 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab 300 mg | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 6 | 14 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ocrelizumab 300 mg | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 5 | 16 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Cluster of Differentiation (CD) 19+B cells(cells/microliters (cells/µL)) | Ocrelizumab 300 mg | Ocrelizumab 600 mg | Total |
|---|---|---|---|
| Median | 287 (160.0 to 635.0) | 234 (73.0 to 512.0) | 246 (73.0 to 635.0) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jan 2020 to primary completion in Oct 2023, 44 months.
Results were first posted in Nov 2024, 1 year 1 month after primary completion.
Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 44 months is above that.
Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab